Shu-Yan Liu

6PUBLICATIONS
3CO-AUTHORS
Molecular targetsCardiology (incl. cardiovascular diseases)Disease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 29, 2021
Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.

Rong Chang, Shu-Yan Liu, Li-Min Zhao

|Aug 16, 2021
Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.

Xue-Yan Duan, Shu-Yan Liu, Dao-Gen Yin

|Jun 23, 2021
Effects of patient characteristics on the efficacy of complete revascularization for treatment of ST-segment elevation myocardial infarction with multivessel disease: A meta-analysis.

Lu-Feng Li, Mei Qiu, Shu-Yan Liu

|Feb 09, 2021
Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors.

Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan

|Jan 12, 2021
Double antithrombotic therapy for prevention of bleeding and ischemic events after percutaneous coronary intervention in patients with atrial fibrillation: A meta-analysis.

Mei Qiu, Shu-Yan Liu, Hai-Rong Zhou

|Jun 01, 2020
Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.

Mei Qiu, Shu-Yan Liu, Jin-Song Gu

Pageof 1

Frequent Collaborators

2 joint publications

Mei Qiu

2 joint publications

Liang-Liang Ding

1 joint publications

Mei Qiu